The Filing Desk

Harrow vs Ironwood Pharmaceuticals

Harrow HROW · Ironwood Pharmaceuticals IRWD · Pharmaceuticals

Ironwood Pharmaceuticals reported revenue of $296 million in fiscal 2025, about the same as Harrow's $272 million in fiscal 2025. Harrow's revenue grew 36.4% in its latest year, and Ironwood Pharmaceuticals' fell 15.7%. Harrow had an operating margin of 11.2%, against 33.3% at Ironwood Pharmaceuticals. Free cash flow was $43 million at Harrow and $127 million at Ironwood Pharmaceuticals.

Side by side

HarrowIronwood Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$272M$296M
Revenue growth36.4%−15.7%
Revenue growth a year, last 5 years41.0%−5.3%
Gross margin75.0%—
Operating margin11.2%33.3%
Net margin−1.9%8.1%
Free cash flow$43M$127M
Free cash flow margin15.8%42.9%
Return on capital——
Net debt to EBITDA5.5x—
Dividends and buybacks$0M$0M
Change in diluted share count3.1%1.8%
Last close$30.12$4.83
P/E at the last close—5.4×
Insider trades, last 12 months——
Piotroski F-score6 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
HarrowIronwood Pharmaceuticals
Operating margin
Percent of revenue
HarrowIronwood Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HarrowIronwood Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Harrow and Ironwood Pharmaceuticals pages.